Inovio Pharmaceuticals (INO) Stock News
$INO · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Inovio Pharmaceuticals (INO) in the past 30 days, 1 of it high impact. BORSA’s news read on INO is bullish at 84/100, −1 over 24 hours, based on 1 company event over the past 7 days. INO last closed at $0.89 on Oct 27, down 11.88% over five sessions and down 23.93% over the past month. Inovio Pharmaceuticals’ next earnings report is scheduled for Monday, Nov 9.
The wire on $INO
newest first · updated · direct subject stories onlyINOVIO received FDA accelerated approval for VOCERYQ, a DNA-based immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis. The approval is based on a 27% complete response rate in the efficacy population. This is the first FDA-approved DNA medicine. INOVIO expects to ship in about 60 days, with full commercial launch in Q1 2027. A confirmatory study is required, with a draft protocol due by end of 2026. INOVIO will host a conference call on November 2 at 8:00 AM ET.
bullish 90 · impact 80The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Inovio Pharmaceuticals (INO) stock: common questions
What is the latest Inovio Pharmaceuticals stock news?
The highest-impact INO story BORSA published in the past 30 days: